Drug Trial Radar · NCT05127434
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36,814
Actual
Start
Nov 17, 2021
Primary completion
Jul 28, 2025
Study completion Jul 28, 2025
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days postinjection through 12 months. The main purpose of Part B of this study is to evaluate the safety, tolerability and immunogenicity of a booster dose (BD) of mRNA-1345 administered 24 months after the primary dose.
Conditions
- Respiratory Syncytial Virus
Interventions
PlaceboDrug
0.9% sodium chloride (normal saline) injection
mRNA-1345Drug
Sterile liquid for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Any Solicited Adverse Reactions (ARs) (Solicited Local and/or Systemic ARs)Time frame: Up to 7 days postinjection
- Part B: Number of Participants With Solicited Local and Systemic ARsTime frame: Up to 7 days post-BD injection
- Part A: Number of Participants With Unsolicited Adverse Events (AEs)Time frame: Up to 28 days postinjection
- Part B: Number of Participants With Unsolicited AEsTime frame: Up to 28 days post-BD injection
- Part A: Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study DiscontinuationTime frame: Up to 24 months postinjection
- Part B: Number of Participants With MAAEs, AESIs, SAEs, and AEs Leading to Study DiscontinuationTime frame: Up to BD Day 181
- Part A: Number of Participants With Respiratory Syncytial Virus- Associated Lower RSV-LRTD With 2 or More Symptoms From 14 Days Postinjection up to 12 Months PostinjectionTime frame: From 14 days postinjection up to 12 months postinjection
- Part A: Number of Participants With RSV-LRTD With 3 or More Symptoms From 14 Days Postinjection up to 12 Months PostinjectionTime frame: From 14 days postinjection up to 12 months postinjection
- Part B: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAb) at BD Day 29 Compared to Primary Dose Day 29Time frame: Primary Dose Day 29 and BD Day 29
Locations
269 sites in 23 countries. Site status is shown where the registry gives one.
AES - DRS - Synexus Clinical Research US, Inc. - Birmingham
Birmingham, Alabama
Accel Research Site - Achieve - Birmingham
Birmingham, Alabama
Lakeview Clinical Research
Guntersville, Alabama
AES - DRS - Optimal Research Alabama - Huntsville
Huntsville, Alabama
Hope Research Institute LLC - Hunt - PPDS
Hunt, Arizona
Hope Research Institute LLC - Hunt - PPDS
Hunt, Arizona
Desert Clinical Research, LLC - CCT
Mesa, Arizona
Hope Research Institute LLC - Phoenix - Hunt - PPDS
Phoenix, Arizona
AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central
Phoenix, Arizona
Synexus Clinical Research US, Inc. - Phoenix Southeast
Phoenix, Arizona
Tucson Neuroscience Research - M3 WR
Tucson, Arizona
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Velocity Clinical Research, Banning
Banning, California
Hope Clinical Research, LLC
Canoga Park, California
Velocity Clinical Research - Chula Vista - PPDS
Chula Vista, California
PPD Virtual - Science 37, Inc
Culver City, California
Velocity Clinical Research, San Diego
La Mesa, California
PRI, LLC - Los Alamitos - M3 WR
Los Alamitos, California
PRI, LLC - Newport Beach - M3 WR
Newport Beach, California
FOMAT Medical Research - FOMAT - HyperCore - PPDS
Oxnard, California
Reddy Care Medical
Pomona, California
Paradigm Clinical Research Institute Inc - ClinEdge - PPDS
Redding, California
Medical Center For Clinical Research - M3 WR
San Diego, California
Lynn Institute of Denver
Aurora, Colorado
Tekton Research - Fort Collins - PPDS
Fort Collins, Colorado
Tekton Research - Longmont - PPDS
Longmont, Colorado
Paradigm Clinical Research Institute Inc - ClinEdge - PPDS
Wheat Ridge, Colorado
Clinical Research Consultants LLC - ClinEdge - PPDS
Milford, Connecticut
Washington Health Institute
Washington D.C., District of Columbia
Velocity Clinical Research, New Smyrna Beach
Edgewater, Florida
Fleming Island Clinical Research Center
Fleming Island, Florida
Velocity Clinical Research - Hallandale Beach - PPDS
Hallandale, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Multi-Specialty Research Associates, Inc. M3 WR
Lake City, Florida
Accel Research Sites - Maitland - ERN - PPDS
Maitland, Florida
Spotlight Research Center, LLC
Miami, Florida
IMA Clinical Research - Manhattan - PPDS
Miami Beach, Florida
AES - DRS - Synexus Clinical Research US, Inc. - The Villages
Orlando, Florida
Health Awareness Inc
Port Saint Lucie, Florida
IMA Clinical Research - Saint Petersburg - PPDS
St. Petersburg, Florida
Showing 40 of 269 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.